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ABSTRACT 
Behçet’s disease (BD) is an autoimmune multisystemic disease. The precise etiology of BD is not fully understood; 
however, it is thought that interactions between genetic and environmental factors play an essential role in its 
pathogenesis. The nuclear receptor coactivator-5 (NCOA5) gene encodes a coregulator for nuclear receptor sub-
family 1 group D member 2 (NR1D2) and estrogen receptor 1 and 2 (ESR1 and ESR2). Also, the NCOA5 gene 
insufficiency leads to an elevated expression of IL-6, and increased levels of IL-6 were found to be related to the 
pathogenesis of BD. In this study, we aimed to clarify the impact of the NCOA5 rs2903908 polymorphism on 
susceptibility and clinical findings of BD. This study included 671 participants (300 BD patients and 371 healthy 
controls). The analyses of NCOA5 rs2903908 polymorphism was performed by using the TaqMan allelic discrim-
ination assay. The frequency of TT genotype of the NCOA5 rs2903908 polymorphism was found significantly 
higher in BD patients compared to those in healthy controls (p=0.016, OR=1.46, 95 % CI=1.08–1.99). Also, the 
frequencies of CT genotype was observed significantly higher in BD patients with genital ulceration and uveitis 
than without genital ulceration and uveitis (p=0.002 and p=0.005, respectively). The most significant association 
was found between C allele frequencies of BD patients with and without uveitis (p=0.0001). Our study represents 
for the first time that the NCOA5 rs2903908 polymorphism seemed to be linked to BD susceptibility and clinical 
findings.  
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INTRODUCTION 
Behçet’s disease (BD) is a multisystemic, 
chronic inflammatory autoimmune disease 
with unknown aetiology and described as a 
triad of recurrent oral aphthous ulcers, genital 
ulceration, and uveitis. The other clinical 
findings include mucocutaneous, articular, 
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neurologic, urogenital, vascular, gastrointes-
tinal, and pulmonary involvements (Gül, 
2005). BD is more prevalent in the geographic 
region along the “Silk Road,” which lies from 
the Mediterranean to the Far East. The preva-
lence of BD in Turkey varies from 20 to 420 
cases per 100,000 adults, which is the highest 
prevalence rate identified in the world (Idil et 
al., 2002; Azizlerli et al., 2003; Cakir et al., 
2004). The male-to-female ratio is nearly 
equal, and the disease occurs in individuals 
aged 18 to 40 years (Gül, 2005; Alpsoy et al., 
2007).  
The precise aetiology of BD is not fully 
understood; however, it is thought that inter-
actions between genetic and environmental 
factors play an essential role in the pathogen-
esis of the disease. Detecting interactions be-
tween the genes and mechanisms playing 
roles in the pathogenesis of numerous dis-
eases can be difficult to find, but there are 
many examples in which common genetic 
factors take part in the development of several 
chronic inflammatory autoimmune diseases 
(Aune et al., 2003; Lee et al., 2012; Oğuz et 
al., 2016). This suggests that certain gene re-
gions may contribute similar pathways that 
are shared by various autoimmune diseases. 
In this field, the CD40 gene was indicated as 
a susceptible gene for a number of chronic in-
flammatory and autoimmune diseases (Gar-
cía-Bermúdez et al., 2012; Joo et al., 2013). 
Additionally, CD40 is a member of tumor ne-
crosis factor receptor superfamily (Foy et al., 
1996). The nuclear receptor coactivator-5 
(NCOA5) gene, located on the 20q13.1 region 
(a 400-kb surrounding zone of the CD40 
gene), encodes a coregulator for nuclear re-
ceptor subfamily 1 group D member 2 
(NR1D2) and estrogen receptor 1 and 2 (ESR1 
and ESR2). NCOA5 is known to modulate the 
ESR1 mediated renewal, proliferation, and 
differentiation of the pluripotent stem cells 
(Naugler et al., 2007; Böser et al., 2013; Sara-
chana and Hu., 2013). On the other hand, 
ESR1 and ESR2 were accepted to take part in 
regulating autoimmunity in systemic lupus er-
ythematosus by promoting the production of 
pathogenic autoantibodies (Bynoté et al., 
2008). Furthermore, the surrounding of 
NCOA5 gene region where the CD40 gene is 
also located includes possible susceptible 
genes of type 2 diabetes mellitus and rheuma-
toid arthritis (Raychaudhuri et al., 2008; 
Lewis et al., 2010). Recently, the significant 
relationship between the NCOA5 rs2903908 
polymorphism and susceptibility to psoriasis, 
which is a T cell mediated chronic inflamma-
tory disease, was also reported (Zervou et al., 
2011). Additionally, genome-wide associa-
tion studies on psoriasis and BD showed that 
these diseases share many common genetic 
risk factors (Lee et al., 2012). Moreover, the 
NCOA5 gene insufficiency leads to an ele-
vated expression of Interleukin (IL)-6, and in-
creased levels of IL-6 were found to be related 
to the pathogenesis of BD (Naugler et al., 
2007; Talaat et al., 2014). These similarities 
led us to consider the NCOA5 gene as a can-
didate for BD. Any association between the 
susceptibility and clinical outcomes of BD 
and the NCOA5 rs2903908 polymorphism 
have not yet been clarified. Therefore, we 
aimed to clarify the impacts of the NCOA5 
rs2903908 polymorphism on susceptibility 
and clinical findings of BD.  
 
MATERIALS AND METHODS 
Sampling and genotyping 
This study included 300 patients with BD 
and 371 ethnicity-matched healthy controls. 
All of the patients had been diagnosed accord-
ing to the criteria of the International Study 
Group for BD (International Team for the Re-
vision of the International Criteria for 
Behçet’s Disease, 2014). Informed consent 
was obtained from all participants before they 
enrolled in this study. The study was per-
formed in accordance with the Declaration of 
Helsinki and was approved by the Ethics 
Committee of Gaziosmanpasa University, 
Faculty of Medicine. Patients, who had any 
autoimmune systemic inflammatory diseases, 
such as rheumatoid arthritis or genetic dis-
eases, were excluded from the study.  
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The age and gender data of the all partici-
pants are given in Table 1. Clinical findings 
of oral aphthae, genital ulceration, skin le-
sions, uveitis, and vascular involvement of the 
patients were noted as present or absent. Skin 
lesions consisted of erythema nodosum or 
papulopustular lesions.  
We performed DNA purification with 
DNA isolation kits from peripheral venous 
blood samples (preserved in EDTA tubes) of 
the patient and control groups. Genetic anal-
yses were performed by using the TaqMan al-
lelic discrimination assay. All SNPs were 
genotyped in the same centre by using a Taq-
Man SNP genotyping assay in a StepOnePlus 
Real-Time Polymerase Chain Reaction 
(PCR) system by following the conditions 
recommended by the manufacturer (Applied 
Biosystems, Foster City, CA, USA).  
We examined the distribution of the 
NCOA5 rs2903908 genotypes and alleles in 
all participants. For further evaluation, we in-
vestigated whether the NCOA5 rs2903908 
polymorphism had impacts on the develop-
ment of any clinical findings such as genital 
ulceration, skin lesions, uveitis, or vascular 
involvement. 
 
Statistical analysis 
Data were analyzed using the Statistical 
Package for Social Sciences (SPSS) software 
version 15.0 for Windows (SPSS Inc., Chi-
cago, IL). Mean and standard deviation were 
used for the presentation of continuous quan-
titative variables. Frequencies and percent-
ages were used for categorical data. The 
NCOA5 rs2903908 overall genotype distribu-
tion was compared by chi-square (χ2) test, and 
the specific genotype and allele distributions 
were compared by using Fisher’s exact test. 
The p-values smaller than 0.05 were consid-
ered significant. The odds ratios (ORs) and 
95 % confidence intervals (CIs) were used to 
determine the relationships between the 
NCOA5 allelic and genotypic variants and 
their occurrence in the patients. The NCOA5 
rs2903908 genotype distributions in both the 
patients and the healthy controls were ana-
lyzed according to the Hardy-Weinberg Equi-
librium (HWE).  
 
RESULTS 
In this study, a total of 300 unrelated 
Turkish patients with BD and 371 individuals 
without any established disease diagnoses 
were evaluated for the rs2903908 polymor-
phism of the NCOA5 gene. The demograph-
ical and clinical findings of all participants are 
summarized in Table 1. The mean age of the 
patients was 37.60 ± 8.85 years, and the mean 
age of the healthy controls was 37.00 ± 11.90 
years. There was no significant difference in 
terms of age and gender between the BD pa-
tients and the healthy controls (p>0.05). Oral 
aphthae were seen in the majority of patients 
(98.48 %).  
 
Table 1: The demographical and clinical findings 
of all participants  
Feature BD 
Patients 
(n=300) 
Controls 
(n=371) 
Age (years) 37.60 ± 
8.85 
37.00 ± 
11.90 
Gender  
(female/male) 148/152 179/192 
Oral aphthae 98.48 % - 
Genital  
ulceration 77.27 % - 
Skin lesions 50.84 % - 
Uveitis 45.21 % - 
Vascular  
involvement 19.00% - 
BD: Behcet’s disease 
 
 
The distributions of the genotypes and al-
leles of the patients and healthy controls for 
the NCOA5 rs2903908 polymorphism are 
presented in Table 2. The frequency of TT 
genotype of the NCOA5 rs2903908 polymor-
phism was significantly higher in patients 
compared to those in healthy controls 
(p=0.016, OR=1.46, 95 % CI=1.08–1.99). 
We found significantly higher levels of the 
CT genotype of the NCOA5 rs2903908 poly-
morphism in healthy controls compared to 
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those in patients with BD (p=0.014, OR=0.66, 
95 % CI=0.49–0.92) (Table 2). The genotype 
distribution of the rs2903908 polymorphism 
of the NCOA5 gene in the patients and con-
trols was compatible to HWE (p>0.05 for all) 
(data not shown).  
We also compared genotype and allele 
distribution of NCOA5 rs2903908 polymor-
phism between patients and controls by gen-
der basis, and we found statistical differences 
for CT and TT genotypes between female pa-
tients and controls (Table 3). In accordance 
with the general result, the CT genotype was 
higher in controls (p=0.014), and the TT gen-
otype was higher in patients (p=0.026) (Table 
3).  
 
 
 
Table 2: The distribution of genotypes and alleles of NCOA5 rs2903908 polymorphism in patients and 
controls 
BD Patients 
(n=300) 
Controls 
(n=371) 
p value OR, 95 % CI 
Genotype  
CC 22 (7.33 %) 27 (7.28 %) 0.052* 
 
 
 
 
CT 108 (36.00 %) 169 (45.55 %) 
TT 170 (56.67 %) 175 (47.17 %) 
HWE p=0.40 p=0.10  
TT : CT+CC 170(56.67 %)/ 
130 (43.33 %) 
175 (47.17 %)/ 
196 (52.83 %) 
0.016¶ 1.46, 1.08-1.99 
CT : CC+TT 108(36.00 %)/ 
192(64.00 %) 
169 (45.55 %)/ 
202 (54.45 %) 
0.014ᵮ 0.67, 0.49-0.92 
Allele  
T 448 (74.67 %) 519 (69.95 %) 0.058§ 1.27, 0.99-1.61 
C 152 (25.33 %) 223 (30.05 %) 
BD: Behcet’s disease, HWE: Hardy-Weinberg Equilibrium, NCOA5: nuclear receptor coactivator-5.  
*-p for genotype distribution, ¶- p for TT vs others, ᵮ- p for CT vs others, §- p for allele distribution. The 
results that are statistically significant are shown in boldface. 
 
 
Table 3: The distribution of genotypes and alleles of NCOA5 rs2903908 polymorphism in patients and 
controls by the gender basis 
Genotypes Male P Female P 
Patients 
(n=152) 
Controls  
(n=192) 
Patients 
(n=148) 
Controls  
(n=179) 
CC 7 (4.61 %) 11 (5.73 %) 0.233* 15 (10.14 %) 16 (8.94 %) 0.112* 
 
 
CT 55 (36.18 %) 80(41.67 %) 53 (35.81 %) 89 (49.72 %) 
TT 90 (59.21 %) 101 (52.60 %) 80 (54.05 %) 74 (41.34 %) 
TT : CT+CC 59.21 %/ 
40.79 % 
52.60 %/ 
47.40 % 
0.231¶ 54.05 %/ 
45.95 % 
41.34 %/ 
58.66 % 
0.026¶
CT : CC+TT 36.18 %/ 
63.82 % 
41.67 %/ 
58.33 % 
0.319ᵮ 35.81 %/ 
64.19 % 
49.72 %/ 
50.28 % 
0.014ᵮ
Alleles   
T 235 
(77.30 %) 
282 (73.44 %) 0.250§ 213 (71.96 %) 237 (66.20 %) 0.127§ 
C 69 (22.70 %) 102 (26.56 %) 83 (28.04 %) 121 (33.80 %) 
*-p for genotype distribution, ¶- p for TT vs others, ᵮ- p for CT vs others, §- p for allele distribution. The 
results that are statistically significant are shown in boldface. 
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The CT genotype of the NCOA5 
rs2903908 polymorphism was significantly 
higher in BD patients with genital ulceration 
(p=0.002, OR=3.03, 95 % CI=1.51–6.08), 
and the TT genotype was higher in BD pa-
tients without genital ulceration (p=0.014, 
OR=0.46, 95 % CI=0.25–0.84). Frequencies 
of C allele and genotypes including C allele 
(CC and CT) were significantly higher in the 
patients with uveitis compared to those with-
out uveitis (p=0.0001, OR=2.19, 
95 % CI=1.48–3.23 and p=0.0002, OR=2.49, 
95 % CI=1.55–3.99, respectively) (Table 4).  
 
 
 
Table 4: The distribution of genotypes and alleles of NCOA5 rs2903908 polymorphism in BD patients 
with and without genital ulceration, skin lesions, uveitis and vascular involvement 
Genotype/Allele Yes No p value OR, 95 % CI 
Genital ulceration 
CC 7.30 % 11.11 % 0.166* 
 
 
 CT 38.93 % 17.78 % 
TT 53.69 % 71.11 % 
TT : CT+CC 53.69 %/46.31 % 71.11 %/28.89 % 0.014¶ 0.46, 0.25-0.84 
CT : CC+TT 38.93 %/61.07 % 17.78 %/82.22 % 0.002 ᵮ 3.03, 1.51-6.08 
T 73.15 % 80.00 % 0.077§ 0.67, 0.43-1.04 
C 26.85 % 20.00 % 
Skin lesions 
CC 6.45 % 8.28 % 0.581*  
CT 35.48 % 36.55 % 
TT 58.07 % 55.17 % 
TT : CT+CC 58.07 %/41.93 % 55.17 %/44.73 % 0.642¶ 1.13, 0.71-1.77 
CT : CC+TT 35.48 %/64.52 % 36.55 %/63.45 % 0.904 ᵮ 0.95, 0.60-1.53 
T 75.81 % 73.45 % 0.880§ 1.13, 0.78-1.63 
C  24.19 % 26.55 % 
Uveitis 
CC 8.24 % 2.91 % 0.0001*  
CT 43.53 % 27.18 % 
TT 48.23 % 69.90 % 
TT : CT+CC 48.23 %/51.77 % 69.90 %/30.10 % 0.0002¶ 0.40, 0.25-0.64 
CT : CC+TT 43.53 %/56.47 % 27.18 %/72.81 % 0.005 ᵮ 2.03, 1.25-3.28 
T 70.00 % 83.50 % 0.0001§ 0.47, 0.31-0.69 
C 30.00 % 16.50 % 
Vascular involvement 
CC 3.51 % 6.58 % 0.470*  
CT 36.84 % 37.04 % 
TT 59.65 % 56.38 % 
TT : CT+CC 59.65 %/40.35 % 56.38 %/43.62 % 0.766¶ 1.14, 0.64-2.05 
CT : CC+TT 36.84 %/63.16 % 37.04 %/62.96 % 1.000 ᵮ 0.99, 0.55-1.79 
T 78.07 % 74.90 % 0.546§ 0.84, 0.52-1.36 
C 21.93 % 25.10 % 
BD: Behcet’s disease, NCOA5: nuclear receptor coactivator-5. *-p for genotype distribution, ¶- p for TT 
vs others, ᵮ- p for CT vs others, §- p for allele distribution. The results that are statistically significant are 
shown in boldface. 
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DISCUSSION 
BD is an inflammatory disorder with re-
current oral aphthous ulcers, genital ulcers, 
and uveitis of which etiology and pathogene-
sis have not been fully elucidated (Gül, 2005). 
Genetic analysis of the multicase families and 
populations demonstrated associations be-
tween BD and genetic factors. Whereas some 
authors reported human leukocyte antigen 
(HLA)-related genes as the predominant ge-
netic risk factors for BD (Kirino et al., 2013; 
Ortiz-Fernández et al., 2016), others sug-
gested several non-HLA genes (Chen et al., 
2012). 
NCOA5 is a nuclear protein with both co-
activator and corepressor domains. It encodes 
a coregulator for ESR1, ESR2 and NR1D2 
(Naugler et al., 2007; Bento et al., 2008; 
Lewis et al., 2010). NR1D2 was demonstrated 
to be upregulated in monocytes from psoriatic 
patients, and this upregulation enabled dis-
ease stage estimation with an accuracy rate of 
86 % based on gene expression patterns (Hor-
nung et al., 2002). However, it was reported 
that NR1D2 gene expression patterns from the 
peripheral blood of rheumatoid arthritis pa-
tients did not differ from that of healthy indi-
viduals (Naugler et al., 2007). On the other 
hand, NCOA5 deficiency resulted in elevated 
IL-6 expression (Liu and Feng, 2014). 
NCOA5 is a known regulator of ESR1 and 
ESR2 which negatively regulate nuclear fac-
tor kappa B-induced IL-6 expression. NCOA5 
haploinsufficiency increases the IL-6 levels 
by disrupting ESR1 mediated repression of 
IL-6 transcription (Naugler et al., 2007). Ta-
laat et al. (2014) showed that BD patients with 
active disease had significantly higher levels 
of IL-6 compared to patients in remission. In 
addition, many other genes indicated an asso-
ciation with BD (Chen et al., 2012; Yazici et 
al., 2012; Hou et al., 2013; Kirino et al., 2013; 
Tasliyurt et al., 2013; Tizaoui et al., 2014; 
Xiang et al., 2014). However, none of these 
genes are fully linked to BD. 
Because NCOA5 can affect many factors 
and pathways, and it can work both as a coac-
tivator and corepressor, perhaps NCOA5 may 
have an impact on BD, especially in females, 
by a way that is not yet undisclosed. This hy-
pothesis was supported by Gao et al. who 
showed that the deletion of both IL-6 alleles 
does not completely block hepatocellular car-
cinoma (HCC) development in NCOA5+/ 
male mice, and other downstream targets of 
NCOA5 may also contribute to hepatocarcin-
ogenesis (Gao et al., 2013). 
Previously, heterozygous deletion in the 
NCOA5 gene was found to be related to in-
creased susceptibility to both glucose intoler-
ance and HCC, partially by elevated IL-6 ex-
pression (Gao et al., 2013). Conversely, 
NCOA5 polymorphisms, including 
rs2903908, were reported not to be related to 
type 2 diabetes mellitus (Lewis et al., 2010). 
However, in a genome-wide association study 
of type 2 diabetes mellitus, the results of 
NCOA5 gene polymorphisms were conflict-
ing (Bento et al., 2008). Moreover, in the pre-
sent study, significant relationship between 
the NCOA5 rs2903908 polymorphism and 
BD were found. Namely, we found that TT 
genotype and the T allele of the NCOA5 
rs2903908 polymorphism were related to an 
increased (approximately one and half-fold) 
susceptibility to BD and it has a protective 
role for genital ulceration and uveitis in this 
study. Also, the CT genotype of the NCOA5 
rs2903908 polymorphism was found to be as-
sociated with an increased development of 
uveitis (approximately two-fold) and genital 
ulceration (approximately three-fold) as well 
as to have a protective role on the develop-
ment of BD (Table 4). Due to overexpression 
of IL-6 associated with genital ulceration and 
uveitis (Talaat et al., 2014), and considering 
the results of recent studies that NCOA5 hap-
loinsufficiency is causing an increase in IL-6 
expression (Sarachana and Hu, 2013; Gao et 
al., 2013), the CT genotype for rs2903908 
polymorphism may also be causing NCOA5 
haploinsufficiency. The rs2903908 polymor-
phism is a T to C transition in the intronic re-
gion of the NCOA5 gene. In the literature, we 
could not find any studies showing the effect 
of the rs2903908 polymorphism on the ex-
pression of NCOA5 gene. A variant in intronic 
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region may form a cryptic splice site that en-
hance the use of that site by making it more 
similar or identical to the normal splice site. 
Therefore, we can consider that the C allele 
reduces the expression of NCOA5. However, 
confirmation of this hypothesis is needed, es-
pecially when considering why the CC geno-
type is not significantly higher in patients 
with genital ulcers and uveitis. Inconsistent 
with our results, Zervou and colleagues 
(2011) reported significantly higher levels of 
the CC genotype and the C allele of the 
NCOA5 rs2903908 polymorphism in patients 
with psoriasis, and they emphasized that the 
CC genotype and the C allele of the NCOA5 
rs2903908 polymorphism might be related to 
an elevated susceptibility to psoriasis (Zervou 
et al., 2011). Our study did not find a signifi-
cant difference for the CC genotype between 
the patients and the control group. These dis-
cordant results may be due to the various un-
derlying pathogenetic mechanisms of the dis-
eases, as well as different ethnic basis and en-
vironmental factors. The study of Gao et al. 
(2013) showed that the NCOA5 gene may be 
impacted positively and negatively by more 
factors than we previously mentioned. Never-
theless, this discrepancy may be clarified by 
future studies investigating the impacts of the 
NCOA5 rs2903908 polymorphism on several 
chronic inflammatory diseases.  
To the best of our knowledge, this prelim-
inary study represents, for the first time, the 
association between the NCOA5 rs2903908 
polymorphism and the susceptibility and clin-
ical findings of BD. We arrived at three main 
results. First, the frequency of TT genotype of 
the NCOA5 rs2903908 polymorphism was 
significantly higher in the female BD patients 
compared to those in the healthy controls, and 
this genotype and allele seemed to be related 
to an increased (approximately one and half-
fold) risk of BD development (p=0.026, 
OR=1.67, 95 % CI=1.08–2.59). In addition, 
the CT genotype of the NCOA5 rs2903908 
polymorphism appeared to prevent individu-
als from developing BD. Second, the CT gen-
otype of the NCOA5 rs2903908 polymor-
phism seemed to predispose the BD patients 
to develop both genital ulceration and uveitis 
more frequently (approximately three-fold for 
genital ulceration and two-fold for uveitis), 
whereas the TT genotype of NCOA5 
rs2903908 polymorphism was found to have 
protective impacts on developing genital ul-
ceration or uveitis in the patients with BD. Fi-
nally, we found that the BD patients who are 
carrying the C allele at the NCOA5 rs2903908 
locus may be more prone to developing uvei-
tis. Although CC genotype was observed 3 
times more in patients with uveitis than with-
out uveitis, the statistically significance was 
not found (8.24 % vs. 2.91 %; p=0.070, 
OR=2.80, 95 % CI=0.93–8.23) (Table 4). 
In conclusion, our study identified that the 
NCOA5 rs2903908 polymorphism seemed to 
be linked to BD susceptibility in females and 
in clinical findings. Additionally, the CD40 
gene, which is located near the region of the 
NCOA5 gene, was previously related to sev-
eral chronic autoimmune inflammatory dis-
eases. We conclude that the NCOA5 gene may 
be a good candidate for future studies investi-
gating genetic tendencies for chronic inflam-
matory and autoimmunity diseases that share 
similar pathogenic pathways. How the 
rs2903908 variant affects the NCOA5 mRNA 
or protein expression and function and how 
this polymorphism influences the pathogene-
sis of BD and its symptoms remain mysteries 
to be solved.  
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